Aflibercept biosimilar (Samsung Bioepis)

阿柏西普生物类似药（Samsung Bioepis）

Report date: 2024/11/27 10:30:37

Base Information

Drug NameAflibercept biosimilar (Samsung Bioepis)
Drug Alias NameAflibercept-yszyOPUVIZOpuvizAFILIVUSB-15 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitorsPlacental Growth Factor inhibitors
TargetsVascular endothelial growth factor APlacental Growth Factor
Therapy Area/IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[7] 
Global Approved IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/05/20
Country/TerritoryCzechiaUnited StatesSingapore +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSamil Pharmaceutical Co LtdBiogen IncSamsung Bioepis Nl Bv +[6] 
Inactive CompaniesN/A
Active IndicationsDiabetic macular oedemaDiabetes ComplicationsRetinal Vein Occlusion +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX44S01LA05
Related LinksN/A